Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › exemestane

exemestane

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of exemestane

58 trials tracked of exemestane: 13 in phase 3 or 4 and 6 with published results. The most-cited published study has 748 citations.

58Trials tracked
13Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 12 Phase 2 35 Phase 1 5 Other / NA 5
  1. Phase 3 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 748 cited
  2. Phase 3 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 727 cited
  3. Phase 3 Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors Completed · 723 cited
  4. Phase 3 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Completed · 562 cited
  5. Phase 3 Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors Completed · 133 cited
  6. Phase 3 Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 Completed · 39 cited
Show 44 more trials
  1. Phase 4 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed
  2. Phase 3 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed
  3. Phase 3 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed
  4. Phase 3 Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer Completed
  5. Phase 3 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed
  6. Phase 3 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer Completed
  7. Phase 3 Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer Completed
  8. Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
  9. Phase 2 A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Completed
  10. Phase 2 Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer Completed
  11. Phase 2 Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients Completed
  12. Phase 2 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors Completed
  13. Phase 2 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis Completed
  14. Phase 2 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Completed
  15. Phase 2 Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer Completed
  16. Phase 2 Palbociclib With Everolimus + Exemestane In BC Completed
  17. Phase 2 Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients Completed
  18. Phase 2 Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer Completed
  19. Phase 2 Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer Completed
  20. Phase 2 A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) Completed
  21. Phase 2 Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Completed
  22. Phase 2 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer Completed
  23. Phase 2 A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy Completed
  24. Phase 2 Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer Completed
  25. Phase 2 Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer Completed
  26. Phase 2 Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Completed
  27. Phase 2 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers Completed
  28. Phase 2 Exemestane in Post-Menopausal Women With NSCLC Completed
  29. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed
  30. Phase 2 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Completed
  31. Phase 2 Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer Completed
  32. Phase 2 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Completed
  33. Phase 2 The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Completed
  34. Phase 2 The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer Completed
  35. Phase 2 Exemestane and Cyclophosphamide for Metastatic Breast Cancer Completed
  36. Phase 2 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer Completed
  37. Phase 2 Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen Completed
  38. Phase 2 Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer Completed
  39. Phase 2 Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer Completed
  40. Phase 2 A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer Completed
  41. Phase 2 Ruxolitinib in Estrogen Receptor Positive Breast Cancer Completed
  42. Phase 2 A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor Completed
  43. Phase 1 BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer Completed
  44. Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 58 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AI plus celecoxib more than doubles odds of clinical response in ER-positive breast cancer
Oncology RCT
AI plus celecoxib more than doubles odds of clinical response in ER-positive breast cancer Adding celecoxib to hormone therapy improves early breast cancer response
This Phase III randomized trial of 269 postmenopausal women with ER-positive resectable breast cancer found that adding celecoxib to an arom…
A new trial shows that adding the drug celecoxib to standard hormone therapy can improve initial clinical responses in postmenopausal women …
medRxiv Jul 18, 2026
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial
OB/GYN & Women's Health RCT
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial A New Pill Combo Helps Women with Advanced Breast Cancer Live Longer
A Phase III RCT of 874 endocrine-pretreated ER+/HER2- advanced breast cancer patients found imlunestrant monotherapy improved median OS vers…
A new pill combo helps women with advanced breast cancer live longer and delays the need for harsh chemotherapy.
Apr 12, 2026